|
Cell Assay Systems
An outstanding network of leading
biological know-how in mammalian and yeast biology has been put in place. This
expertise ranges from a platform of in vitro and in vivo protein-protein
interaction screening technologies to the use of high content, information rich,
cell-based assays and gene-reporter cell lines.
 
These assays form the basis of NexusPharma’s chemical genomics approach, and
provide the read-outs for a wide range of signaling pathways of physiologically
relevant protein interactions. Further, NexusPharma is using yeast two-hybrid,
mass spectrometry, protein NMR and protein X-ray technologies to validate the
binding of small molecule protein interaction inhibitors.
Bioinformatics tools are being developed to assess whether the drug has effectively
modified the activity of the oncoprotein and whether the drug has separately
affected off-target signaling pathways. A model of the signaling network in
the cell of interest is created and probed to ascertain whether the transcriptional
responses seen indicate that the pathway activity has changed.
NexusPharma integrates the design and application of chemo- and bio-informatics
algorithms with its cell based assay systems, resulting in a multi-disciplinary
approach characterized by state-of-the-art medicinal chemistry, innovative biology
and development. This process provides the basis for the Company’s value proposition
– the creation of novel small molecule compounds that will become the drugs
of the future, improving the quality of human life.
|
